The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).

被引：9

作者：

Jonker, Derek J.

Nott, Louise M.

Yoshino, Takayuki

Li, Chiang

Gill, Shariene

Shapiro, Jeremy David

Ohtsu, Atsushl

Zalcberg, John Raymond

Vickers, Michael M.

Slims, John

Wei, Alice Chia-Chi

Mittmann, Nicole

Magoski, Nadine M.

Murray, Yvonne

Tsobanis, Eric

Tu, Dongsheng

Kerstein, David

O'Callaghan, Christopher J.

机构：

[1] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[2] Royal Hobart Hosp, Hobart, Tas, Australia

[3] Natl Canc Ctr Hosp East, Chiba, Japan

[4] Boston Biomed Inc, Cambridge, MA USA

[5] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[6] Cabrini Hosp, Melbourne, Vic, Australia

[7] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] Tom Baker Canc Clin, Calgary, AB, Canada

[10] NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[11] Toronto Gen Hosp, Toronto, ON, Canada

[12] Sunnybrook Hlth Sci Ctr, HOPE Res Ctr, Toronto, ON M4N 3M5, Canada

[13] NCIC Clin Trials Grp, Kingston, ON, Canada

[14] NHMRC Clin Trials Ctr, Camperdown, NSW, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.tps3660

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS3660

引用

页数：1

共 50 条

[21] Vinorelbine (VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (Pts). Results of a phase III randomized trial
Gridelli, C
Ianniello, GP
Maiorino, L
Brancaccio, L
Cigolari, S
Bilancia, D
Aiello, R
Zuccarino, L
Pedicini, T
Zonato, S
Pappagallo, GL
Monfardini, S
Rossi, A
Gallo, C
Perrone, F
BRITISH JOURNAL OF CANCER, 1998, 78 : 3 - 3
[22] Vinorelbine(VNR) plus best supportive care (BSC) vs BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trial
Gridelli, C
Ianniello, GP
Maiorino, L
Piantedosi, V
Cigolari, S
Manzione, L
Failla, G
Zuccarino, L
Pedicini, T
Vinante, O
Castiglione, F
Clerici, M
Bearz, A
Darwish, S
Rossi, A
Monfardini, S
Gallo, C
Perrone, F
Frontini, L
ANNALS OF ONCOLOGY, 1998, 9 : 85 - 85
[23] Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
Abou-Alfa, G. K.
Qin, S.
Ryoo, B-Y.
Lu, S-N.
Yen, C-J.
Feng, Y-H.
Lim, H. Y.
Izzo, F.
Colombo, M.
Sarker, D.
Bolondi, L.
Vaccaro, G.
Harris, W. P.
Chen, Z.
Hubner, R. A.
Meyer, T.
Sun, W.
Harding, J. J.
Hollywood, E. M.
Ma, J.
Wan, P. J.
Ly, M.
Bomalaski, J.
Johnston, A.
Lin, C-C.
Chao, Y.
Chen, L-T.
ANNALS OF ONCOLOGY, 2018, 29 (06) : 1402 - 1408
[24] A prospective, randomized, double-blinded, placebo controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.
Kang, Yoon-Koo
Boku, Narikazu
Kang, Won Ki
Yoon, Harry H.
Cascinu, Stefano
Al-Batran, Salah-Eddin
Houston, Scott
Park, Cheol Hee
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] RESULTS OF A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL (CORRECT) OF REGORAFENIB PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WHO HAVE PROGRESSED AFTER STANDARD THERAPIES
Yoshino, T.
Van Cutsem, E.
Sobrero, A. F.
Siena, S.
Falcone, A.
Ychou, M.
Lenz, H. -J.
Cihon, F.
Wagner, A.
Grothey, A.
ANNALS OF ONCOLOGY, 2012, 23 : 7 - 7
[26] Comorbidity and overall survival (OS) in cetuximab-treated patients with advanced colorectal cancer (ACRC)-Results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care (BSC)
Powell, E. D.
Asmis, T.
Jonker, D.
Tu, D.
Karapetis, C.
Jeffery, M.
O'Callaghan, C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[27] The CCTG C0.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.
Chen, Eric Xueyu
Jonker, Derek J.
Kennecke, Hagen F.
Koski, Sheryl L.
Wei, Alice Chia-chi
Magoski, Nadine M.
Tu, Dongsheng
O'Callaghan, Christopheri J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study
Lenz, Heinz-Josef
Tabernero, Josep
Yoshino, Takayuki
Lonardi, Sara
Falcone, Alfredo
Miron, Maria Luisa Limon
Saunders, Mark P.
Sobrero, Alberto F.
Park, Young Suk
Monteagudo, Reyes Ferreiro
Hong, Yong Sang
Tomasek, Jiri
Taniguchi, Hiroya
Ciardiello, Fortunato
Sassi, Mouna
Peil, Barbara
Hastedt, Claudia
Studeny, Matus
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[29] PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
Paz-Ares, L. G.
De Marinis, F.
Dediu, M.
Thomas, M.
Pujol, J.
Bidoli, P.
Molinier, O.
Sahoo, T. P.
Laack, E.
Reck, M.
Corral, J.
Melemed, S. A.
John, W. J.
Chouaki, N.
Zimmerman, A.
Grul, C. M. Visseren
Gridelli, C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[30] PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
Paz-Ares, L. G.
De Marinis, F.
Dediu, M.
Thomas, M.
Pujol, J.
Bidoli, P.
Molinier, O.
Sahoo, T. P.
Laack, E.
Reck, M.
Corral, J.
Melem, S. A.
Grul, C. M. Visseren
Gridelli, C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)

← 1 2 3 4 5 →